Your Article Summary
See Latest ArticlesStage IIIA-N2 NSCLC: A review of its treatment approaches and future developments
Lung Cancer, 06/26/09
Van Meerbeeck JP et al. - This manuscript reviews the reasons and the biases inherent to this controversy and discusses the different treatment approaches with emphasis on survival as evidenced by meta-analyses and large randomised clinical trials. Prospects on novel treatment modalities and future research opportunities are presented.
Related Articles
Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related Non-Small Cell Lung Cancer Through Aberrant Methylation and Alterations of EGFR Signaling
Annals of Surgical Oncology, 10/23/09
Relevance Score: 89%
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Relevance Score: 87%
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
Journal of Clinical Oncology, 10/29/09
Relevance Score: 85%
Expression and Significance of Clusterin in Anip973/CDDP Cell Lines
Chinese Journal of Lung Cancer, 10/23/09
Relevance Score: 85%
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 85%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
The combination of Young's syndrome and small cell lung cancer—A spiky connection
Lung Cancer, 12/17/09
DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type
Lung Cancer, 12/17/09
Cine MRI enables better therapeutic planning than CT in cases of possible lung cancer chest wall invasion
Lung Cancer, 12/17/09